Nervermind the road shows. What is most crucial now is revealing excellent data for LYMPRO and MANF. I think AMBS' OTC listing and penny stock price has kept deep pocketed investors on the sidelines until the company shows that Lympro is as promised and selling along with an uplist onto a major exchange. That "should" lure the big investors off of the sidelines and into the game.